<p>We announced an agreement that Vertex Pharmaceuticals will acquire Crinetics Pharmaceuticals, further advancing our programs and supporting our patients.</p>

Peer-reviewed Journal Articles

March 17, 2026

Rapid and Sustained Response of Biochemically Uncontrolled Acromegaly to Once-daily Oral Paltusotine Treatment.

J Clin Endocrinol Metab. 2026 Mar 17;111(4):e1050-e1063

Biller BMK, Casagrande A, Elenkova A, Boguszewski CL, Jallad RS, Hu B, Hubina E, Fazeli PK, Fleseriu M, Snyder PJ, Strasburger CJ, Bidlingmaier M, Zhao Y, Soares B, Trainer PJ, Struthers RS, Krasner A, Gadelha MR.

View Original Source

May 19, 2026

Efficacy and safety of pharmacologic therapies in acromegaly: a systematic literature review and network meta-analysis.

J Clin Endocrinol Metab. 2026 May 19;111(6):1786-1799

Salvatori R, Colzani RM, Hummel N, Kopiec A, Maliszewska Z, Wang S, Okeyo JC, Cuddihy RM, Nachtigall LB.

View Original Source

July 2025

Oral paltusotine, a nonpeptide selective somatostatin receptor 2 agonist: Mass balance, absolute bioavailability and metabolism in healthy participants.

Br J Clin Pharmacol. 2025 Jul;91(7):2070-2079.

Luo R, Madan A, Ferrara-Cook CT, Dalvie D, Goulet L, Struthers RS, Krasner AS.

View Original Source

November 2025

Continuous Glucose Monitoring-Derived Glycemic Phenotyping of Childhood Hypoglycemia Due to Hyperinsulinism: A Year-long Prospective Nationwide Observational Study.

J Diabetes Sci Technol. 2025 Nov;19(6):1528-1537.

Worth C, Auckburally S, Worthington S, Ahmad S, O'Shea E, Senniappan S, Shaikh G, Dastamani A, Ferrara-Cook C, Betz S, Salomon-Estebanez M, Banerjee I.

View Original Source

December 5, 2025

Real-world burden of disease, treatment, and healthcare resource utilization in acromegaly: a quantitative survey of patient experiences.

J Patient Rep Outcomes. 2025 Dec 5;9(1):140

Koobatian M, Sisco J, Okeyo JC, Krasner A, Quock TP.

View Original Source

March 19, 2024

Discovery of CRN04894: A Novel Potent Selective MC2R Antagonist.

ACS Med Chem Lett. 2024 Mar 19;15(4):478-485.

Kim SH, Han S, Zhao J, Wang S, Kusnetzow AK, Reinhart G, Fowler MA, Markison S, Johns M, Luo R, Struthers RS, Zhu Y, Betz SF.

View Original Source

December 18, 2024

Acromegaly Disease Control Maintained After Switching From Injected Somatostatin Receptor Ligands to Oral Paltusotine.

J Clin Endocrinol Metab. 2024 Dec 18;110(1):228-237.

Gadelha MR, Casagrande A, Strasburger CJ, Bidlingmaier M, Snyder PJ, Guitelman MA, Boguszewski CL, Buchfelder M, Shimon I, Raverot G, Tóth M, Mezősi E, Doknic M, Fan X, Clemmons D, Trainer PJ, Struthers RS, Krasner A, Biller BMK.

View Original Source

February 15, 2023

Development and evaluation of the Acromegaly Symptom Diary.

J Patient Rep Outcomes. 2023 Feb 15;7(1):15.

Martin S, Bender RH, Krasner A, Marmon T, Monahan M, Nelson L.

View Original Source

April 13, 2023

ACROBAT Edge: Safety and Efficacy of Switching Injected SRLs to Oral Paltusotine in Patients With Acromegaly.

J Clin Endocrinol Metab. 2023 Apr 13;108(5):e148-e159.

Gadelha MR, Gordon MB, Doknic M, Mezősi E, Tóth M, Randeva H, Marmon T, Jochelson T, Luo R, Monahan M, Madan A, Ferrara-Cook C, Struthers RS, Krasner A.

View Original Source

June 2023

A selective nonpeptide somatostatin receptor 5 agonist effectively decreases insulin secretion in hyperinsulinism.

J Biol Chem. 2023 Jun;299(6):104816.

Juliana CA, Chai J, Arroyo P, Rico-Bautista E, Betz SF, De León DD.

View Original Source

December 10, 2022

Discovery of Paltusotine (CRN00808), a Potent, Selective, and Orally Bioavailable Non-peptide SST2 Agonist.

ACS Med Chem Lett. 2022 Dec 10;14(1):66-74.

Zhao J, Wang S, Markison S, Kim SH, Han S, Chen M, Kusnetzow AK, Rico-Bautista E, Johns M, Luo R, Struthers RS, Madan A, Zhu Y, Betz SF.

View Original Source

September 27, 2022

Somatostatin receptors in congenital hyperinsulinism: Biology to bedside.

Front Endocrinol (Lausanne). 2022 Sep 27;13:921357.

van Albada ME, Mohnike K, Dunne MJ, Banerjee I, Betz SF.

View Original Source

September 1, 2022

Discovery of 4-(3-aminopyrrolidinyl)-3-aryl-5-(benzimidazol-2-yl)-pyridines as potent and selective SST5 agonists for the treatment of congenital hyperinsulinism.

Bioorg Med Chem Lett. 2022 Sep 1;71:128807

Zhao J, Wang S, Hee Kim S, Han S, Rico-Bautista E, Sturchler E, Nguyen J, Tan H, Staley C, Karin Kusnetzow A, Betz SF, Johns M, Goulet L, Luo R, Fowler M, Athanacio J, Markison S, Scott Struthers R, Zhu Y.

View Original Source

April 2022

Paltusotine, a novel oral once-daily nonpeptide SST2 receptor agonist, suppresses GH and IGF-1 in healthy volunteers.

Pituitary. 2022 Apr;25(2):328-339

Madan A, Markison S, Betz SF, Krasner A, Luo R, Jochelson T, Lickliter J, Struthers RS.

View Original Source

November 1, 2020

Discovery of substituted 3H-pyrido[2,3-d]pyrimidin-4-ones as potent, biased, and orally bioavailable sst2 agonist.

Bioorg Med Chem Lett. 2020 Nov 1;30(21):127496

Zhao J, Chen Z, Kusnetzow AK, Nguyen J, Rico-Bautista E, Tan H, Betz SF, Struthers RS, Zhu Y.

View Original Source

September 1, 2020

Discovery of nonpeptide 3,4-dihydroquinazoline-4-carboxamides as potent and selective sst2 agonists.

Bioorg Med Chem Lett. 2020 Sep 1;30(17):127391

Zhao J, Wang S, Han S, Kim SH, Kusnetzow AK, Nguyen J, Rico-Bautista E, Tan H, Betz SF, Scott Struthers R, Zhu Y.

View Original Source